Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Vaccine Results A Breakthrough Moment For BioNTech

Founder Considers Its Focus To Be Immunotherapy, Not mRNA

Executive Summary

Approval for the first-to-market COVID-19 vaccine would transform BioNTech – but major challenges in meeting global demand and for its oncology pipeline await.

You may also be interested in...



Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy

The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things. 

Pfizer And BioNTech Claim COVID-19 Vaccine Success

The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel